prijavaregistracija

košarica

0.00 €
HPLC testiranoCOA vsaka serijaEU dostavaSEPA · varno plačiloResearch Use Only
PEPTIQA BIOTECHSemaglutide10 mgPurity 8% · RUO

Excellent

Ocena 4.8 / 5 — zgodnja ocena kakovosti

★Peptiqa Reviews

Zgodnja ocena kakovosti — po prvem verified nakupu lahko kupci objavijo mnenje.

Semaglutide

10 mg8% purityLot #SEMAGL-2026-001

Šifra izbrane dimenzije: PEP-SEMA-10MG

Semaglutide is a synthetic agonist of the GLP-1 (Glucagon-Like Peptide-1) receptor that shares approximately 94% structural similarity with endogenous human GLP-1. Initially designed as a therapeutic option for type 2 diabetes, it has since become one of the most extensively studied compounds in metabolic science. By replicating the activity of the natural incretin hormone GLP-1, Semaglutide activates GLP-1 receptors located throughout the pancreas, central nervous system, and gastrointestinal tract. This receptor stimulation promotes glucose-dependent insulin secretion, reduces glucagon output, slows the rate of gastric emptying, and influences hypothalamic pathways involved in appetite regulation, leading to lower caloric intake. Findings from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical program reported average body weight reductions ranging from 14.9% to 17.4% over a 68-week period. Additional studies published in the New England Journal of Medicine have demonstrated meaningful cardiovascular benefits, including a reduced incidence of major adverse cardiovascular events.
€230.58z DDV
✅ Na zalogi (40)

Količinski popusti

KoličinaCena / kosPrihranek
1 vial230.58 €—
3 vials (−7%)214.72 €−7%
5 vials (−12%)202.52 €−12%
Nakup & zberi 189 točk!

Ocene in mnenja

Prijavite se in ocenite izdelek po prejetem naročilu. prijava

Certifikat analize

Lab Verified
✓Ogled COA pred nakupom — transparentnost zagotovljena
Raziskovalni profil

Semaglutide — znanstveni profil

Vsebina je namenjena izobraževalnim in raziskovalnim namenom. Research Use Only.

  • Semaglutide is a synthetic agonist of the GLP-1 (Glucagon-Like Peptide-1) receptor that shares approximately 94% structural similarity with endogenous human GLP-1. Initially designed as a therapeutic option for type 2 diabetes, it has since become one of the most extensively studied compounds in metabolic science. By replicating the activity of the natural incretin hormone GLP-1, Semaglutide activates GLP-1 receptors located throughout the pancreas, central nervous system, and gastrointestinal tract. This receptor stimulation promotes glucose-dependent insulin secretion, reduces glucagon output, slows the rate of gastric emptying, and influences hypothalamic pathways involved in appetite regulation, leading to lower caloric intake. Findings from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical program reported average body weight reductions ranging from 14.9% to 17.4% over a 68-week period. Additional studies published in the New England Journal of Medicine have demonstrated meaningful cardiovascular benefits, including a reduced incidence of major adverse cardiovascular events.

Več iz kategorije Metabolizem

BPC-157
BPC-157
€114.68
TB-500
TB-500
€119.56
Glutathione
Glutathione
€87.84
GHK-Cu
GHK-Cu
€103.70

Ta stran uporablja piškotke

Accept